Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell LymphomaMichael R. Bishop, Jason R. Westin, Armando Santoro et al.|New England Journal of Medicine|2021Cited by 532
Tisagenlecleucel Vs Standard of Care As Second-Line Therapy of Primary Refractory or Relapsed Aggressive B-Cell Non-Hodgkin Lymphoma: Analysis of the Phase III Belinda StudyMichael Bishop, Jason R. Westin, Michael Dickinson et al.|Blood|2021Cited by 15